This Gastrointestinal Stromal Tumor (GIST)- Epidemiology Forecast-2032' report delivers an in-depth understanding of the Gastrointestinal Stromal Tumor (GIST), historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor (GIST) trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
GIST progression is driven by mutations in KIT or PDGFRA or by other rare gene alterations, all of which are mutually exclusive. It is known that the majority of tumors of GIST will have mutations in the KIT gene, and a minority, in the PDGFR gene.
Wild-type GIST do not have mutations of the KIT or PDGFR genes. Some of the cases of wild-type GIST have been linked to genes involved in the succinate dehydrogenase (SDH) enzyme complex (i.e., SDHA, SDHB, SDHC, or SDHD genes). Additional genes have been linked to wild-type GIST, includes BRAF, KRAS, and NRAS mutations.
After physical examination, CT scan (CAT scan), MRI, Endoscopic ultrasound, biopsy, Immunohistochemistry, Mitotic rate, PET scan can be performed to confirm the disease and its severity.
Gastrointestinal Stromal Tumor (GIST) Disease Understanding
As per GIST Support International, gastrointestinal stromal tumor (GIST) is rare cancer affecting the digestive tract or nearby structures within the abdomen. It is a sarcoma that arises either from cells called interstitial cells of Cajal (ICCs) or from less differentiated stem cells or precursor cells that can develop into ICCs.GIST progression is driven by mutations in KIT or PDGFRA or by other rare gene alterations, all of which are mutually exclusive. It is known that the majority of tumors of GIST will have mutations in the KIT gene, and a minority, in the PDGFR gene.
Wild-type GIST do not have mutations of the KIT or PDGFR genes. Some of the cases of wild-type GIST have been linked to genes involved in the succinate dehydrogenase (SDH) enzyme complex (i.e., SDHA, SDHB, SDHC, or SDHD genes). Additional genes have been linked to wild-type GIST, includes BRAF, KRAS, and NRAS mutations.
Gastrointestinal Stromal Tumor (GIST) Diagnosis
A GIST diagnosis is typically made or ruled out based on a patient's medical history, a comprehensive physical examination, and the results of a series of tests. The testing methods used to confirm or rule out a GIST can vary based on a patient's symptoms and other individual factors.After physical examination, CT scan (CAT scan), MRI, Endoscopic ultrasound, biopsy, Immunohistochemistry, Mitotic rate, PET scan can be performed to confirm the disease and its severity.
Gastrointestinal Stromal Tumor (GIST) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total incident cases of GIST, Gender-specific Incident Cases of GIST, Age-specific Incident Cases of GIST, Incident Cases of GIST by Mutation, and Stage-specific Incident Cases of GIST in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2032.Gastrointestinal Stromal Tumor (GIST) Detailed Epidemiology Segmentation
- In the assessment done by the publisher, the estimated total incident cases of GIST in the 7MM were 14,251 in 2021.
- The highest incident cases of GIST were accounted by the US in 2021 (6,035 cases), which are expected to show a steep rise soon due to the improvement in diagnostic testing and advancements in genetic testing and accounts for 42% of the total cases in the 7MM.
- In 2021, the age-specific incident cases of GIST accounted highest in the age group 66-80 years with 5,384 cases in the 7MM, followed by age group 51-65 years with 4,581 cases. While the least number of cases were seen in the age group 0-17 years.
- Among the European countries, Germany had the highest incident population of GIST with 1,736 cases, followed by Italy, which had incident population of 1,095 in 2021. On the other hand, Spain had the lowest incident population (824 cases).
- Japan had 2,458 incident cases for GIST in 2021, accounting for approximately 17% of total incident cases in the 7MM.
Scope of the Report
- The report covers the descriptive overview of Gastrointestinal Stromal Tumor (GIST), explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden of Gastrointestinal Stromal Tumor (GIST).
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
Report Highlights
- 11-Year Forecast of Gastrointestinal Stromal Tumor (GIST)
- 7MM Coverage
- Total Incident Cases of GIST
- Gender-specific Incident Cases of GIST
- Age-specific Incident Cases of GIST
- Mutation-specific Incident Cases of GIST
- Stage-specific Incident Cases of GIST
Key Questions Answered
- What are the disease risk and burden of Gastrointestinal Stromal Tumor (GIST)?
- What is the historical Gastrointestinal Stromal Tumor (GIST) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Gastrointestinal Stromal Tumor (GIST) at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Gastrointestinal Stromal Tumor (GIST)?
- Out of the above-mentioned countries, which country would have the highest incident population of Gastrointestinal Stromal Tumor (GIST) during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Reasons to Buy
The Gastrointestinal Stromal Tumor (GIST) report will allow the user to -- Develop business strategies by understanding the trends shaping and driving the 7MM Gastrointestinal Stromal Tumor (GIST) epidemiology forecast.
- The Gastrointestinal Stromal Tumor (GIST) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The Gastrointestinal Stromal Tumor (GIST) epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Table of Contents
1. Key Insights2. Report Introduction4. Gastrointestinal Stromal Tumor: Future Perspective5. Executive Summary of Gastrointestinal Stromal Tumors6. Patient Journey9. Key Opinion Leaders' Views11. Publisher Capabilities12. Disclaimer13. About the Publisher
3. Gastrointestinal Stromal Tumor Epidemiology Overview at a Glance
7. Gastrointestinal Stromal Tumor: Disease Background and Overview
8. Epidemiology and Patient Population
10. Appendix
List of Tables
List of Figures
